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Background. Natural killer cell function is regulated by inhibitory and activating killer cell immunoglobulin-like receptors (KIR).
Previous studies have documented associations of KIR genotype with the risk of cytomegalovirus (CMV) replication after solid or-
gan transplantation.Methods. In this study of 649 solid organ transplant recipients, followed prospectively for infectious disease
events within the Swiss Transplant Cohort Study, we were interested to see if KIR genotype associated with virus infections other
than CMV.Result.We found that KIR B haplotypes (which have previously been linked to protection from CMV replication) were
associated with protection from varicella zoster virus infection (hazard ratio, 0.43; 95% confidence interval, 0.21-0.91; P = 0.03).
No significant associations were detected regarding the risk of herpes simplex, Epstein-Barr virus or BK polyomavirus infections.
Conclusions. In conclusion, these data provide evidence that the relative protection of KIR haplotype B from viral replication
after solid organ transplantation may extend beyond CMV to other herpes viruses, such as varicella zoster virus and possibly
Epstein-Barr virus.
(Transplantation 2015;00: 00–00)
Natural killer (NK) cells are important in the early re-sponse against many pathogens including viruses. In con-
trast to B and T lymphocytes, they do not express rearranged
surface receptors. Instead, diversity in the NK cell repertoire is
a function of expression of varied combinations of inhibitory
and activating surface receptors. It has been shown recently that
Received 25 October 2014. Revision requested 31 January 2015.
Accepted 19 February 2015.
1 Immunotherapy Laboratory, Department of Biomedicine, University Hospital, Basel,
Switzerland.
2 Infectious Diseases and Hospital Epidemiology, University Hospital, Basel, Switzerland.
3 Transplantation and Clinical Virology, Department of Biomedicine, University of
Basel, Basel, Switzerland.
4 Departments of Internal Medicine and Infectious Diseases, Clinica Luganese,
Lugano, Switzerland.
5 Department of InfectiousDiseases, Inselspital, Bern University Hospital andUniversity
of Bern, Bern, Switzerland.
6 Service of Infectious Diseases, University Hospital, Geneva, Switzerland.
7 Division of Infectious Diseases and Hospital Hygiene, Kantonsspital, St. Gallen,
Switzerland.
8 Division of Infectious Diseases and Hospital Epidemiology, University Hospital
Zurich, Switzerland.
9 Division of Infectious Diseases and Hospital Epidemiology, University Children's
Hospital, Zurich, Switzerland.
10 Transplant Immunology Unit, Division of Immunology and Allergy, University
Hospital, Geneva, Switzerland.
11 Infectious Diseases Service and Transplantation Center, University Hospital and
University of Lausanne, Switzerland.
12 Immunobiology Laboratory, Department of Biomedicine, University Hospital,
Basel, Switzerland.
This study has been conducted in the framework of the Swiss Transplant Cohort
Study, supported by the Swiss National Science Foundation and the Swiss Univer-
sity Hospitals (G15) and transplant centers. This work was supported by the Swiss Na-
tional Science Foundation (PP00P3_128461/1 to MS, and 310030_153059 to CH).
This work was supported by the Freiwillige Akademische Gesellschaft, Basel.
The authors declare no conflict of interest.
L.S. analyzed the data and wrote the article. G.T. wrote the article. A.G. and K.S.
performed the research and wrote of the article. H.H.H., C.G., C.vD., K.B., N.J.M.,
C.B., J.V., O.M., P.M., and C.H. analyzed data and wrote the article. M.S.
designed the research, analyzed the data, and wrote the article.
Themembers of the Swiss Transplant Cohort Study are: Rita Achermann, John-David
Aubert, Philippe Baumann, Guido Beldi, Christian Benden, Christoph Berger, Thierry
Berney, Isabelle Binet, Pierre-Yves Bochud, Elsa Boely (Head of local data
management), Heiner Bucher, Leo Bühler, Thierry Carell, Emmanuelle Catana, Yves
Chalandon, Sabina de Geest, Olivier de Rougemont, Michael Dickenmann, Michel
Duchosal, Thomas Fehr, Sylvie Ferrari-Lacraz, Christian Garzoni, Yvan Gasche,
Paola Gasche Soccal, Emiliano Giostra, Déla Golshayan, Daniel Good, Karine
Hadaya, Christoph Hess, Sven Hillinger, Hans Hirsch, Günther Hofbauer, Uyen
Huynh-Do, Franz Immer, Richard Klaghofer, Michael Koller (Head of the data center),
Thomas Kuntzen, Bettina Laesser, Roger Lehmann, Christian Lovis, Oriol Manuel,
Hans-Peter Marti, Pierre Yves Martin, Pascal Meylan, Paul Mohacsi, Isabelle
Morard, Philippe Morel, Ulrike Mueller, Nicolas Mueller (Chairman Scientific
Committee), Helen Mueller-McKenna, Thomas Müller, Beat Müllhaupt, David
Nadal, Gayathri Nair, Manuel Pascual (Executive office), Jakob Passweg, Chantal
Piot Ziegler, Juliane Rick, Eddy Roosnek, Anne Rosselet, Silvia Rothlin, Frank
Ruschitzka, Urs Schanz, Stefan Schaub, Christian Seiler, Nasser Semmo,
Susanne Stampf, Jürg Steiger (Head, Excecutive office), Dimitri Tsinalis, Christian
Van Delden (Executive office), Jean-Pierre Venetz, Jean Villard, Madeleine Wick
(STCS coordinator), Markus Wilhlem, Patrick Yerly.
Correspondence: Martin Stern, MD, Immunotherapy Laboratory, Department
of Biomedicine, University Hospital Basel, Hebelstrasse 20, CH-4031 Basel,
Switzerland. (martin.stern@usb.ch).
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN: 0041-1337/15/0000-00
DOI: 10.1097/TP.0000000000000778
OriginalClinicalScience
Transplantation ■ Month 2015 ■ Volume 00 ■ Number 00 www.transplantjournal.com 1
Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
thousands of differentNK cell phenotypes exist within the poly-
clonal pool of healthy donor NK cells.1
Among the most polymorphic NK cell receptors are killer-
cell immunoglobulin-like receptors (KIR). The KIR can be
either activating or inhibitory in nature, depending on the struc-
ture of their intracellular tail containing an immunoreceptor
tyrosine-based inhibitory or activating motif (immunoreceptor
tyrosine-based inhibitory motif/immunoreceptor tyrosine-
based activating motif).2 Inhibitory KIRmediate NK cell toler-
ance by binding to self-HLA class I molecules. By contrast, the
ligands and physiological relevance of activating KIRs are only
poorly understood; binding to HLA class I has only been doc-
umented for KIR2DS1, KIR2DS2, and KIR2DS4.3-5 The KIR
genes segregate as haplotypes, which are classified as “A” if
they contain a canonical set of six inhibitory receptors and 1
single activating KIR gene (KIR2DS4), whereas the remaining
haplotypes,whichmay contain up to 5 additional activating re-
ceptors, are collectively classified as “B.” In whites, A and B
haplotypes are found at similar frequencies. Recipient B haplo-
type and high numbers of activating KIR genes have been
linked with protection from cytomegalovirus replication after
solid organ transplantation (SOT) in a number of studies.6,7
More recently, several studies have suggested that KIR genes
may also associate with the risk for other viral infections, such
as hepatitis C,8 herpes simplex,9 BK polyomavirus (BKPyV),10
and influenza.11 For Epstein-Barr virus (EBV) and varicella zos-
ter virus (VZV), 2 further members of the human herpes virus
family, evidence for involvement of NK cells in disease control
recently emerged, but no possible correlation with KIR geno-
type has been investigated yet.12,13 For several of the above-
mentioned viruses, different receptors were shown to be
involved in the innate immune response.14-16 At the same time,
all these receptors are present in every individual. In contrast,
KIR receptors vary in number and composition between indi-
viduals. A possible influence of single KIR receptors might
therefore operate as a prognostic marker. As virus infection/
replication is a frequent complication of immunosuppression
after SOT, we were interested to analyze the correlation of
KIR genotype and virus replication after SOT.
Wemade use of the Swiss Transplant Cohort Study, a large
prospectivemulticenter effort collecting data and bio samples
on all solid organ transplants performed in Switzerland,17 to
address whether recipient KIR genotype associates with the
risk of viral infections in recipients of SOT.
PATIENTS AND MATERIALS
Patients
Six hundred forty-nine patients undergoing single SOT at 6
transplant centers in Switzerland between May 2008 and
December 2010 were combined in this analysis (Inselspital
Bern, n = 99; Centre Hospitalier Universitaire Vaudois, n = 102;
Hôpitaux Universitaires de Genève, n = 95; Kantonsspital St.
Gallen, n=15;Universitätsspital Basel, n =106;Universitätsspital
Zürich, n = 232). Induction and maintenance immunosuppres-
sive regimens in patients grouped by KIR haplotype are summa-
rized in Table 1 along with demographic characteristics.
Data on transplant characteristics and transplant outcome
including infectious complications were prospectively col-
lected and retrieved using an electronic database.17 Written
informed consent was obtained from all study participants,
and the study was approved by the institutional review
boards in all centers.
KIR Genotyping
The KIR genotyping was performed using a reverse
sequence-specific oligonucleotide method (OneLambda,
Canoga Park, CA) according to the manufacturer's instruc-
tions,7 these results were in part reconfirmed by quantitative
polymerase chain reaction (qPCR).18 The KIR genotypes
were grouped into AA if they contained only the canonical
group A haplotype genes (KIR2DL1, KIR2DL3, KIR2DL4,
KIR3DL1, KIR3DL2, KIR3DL3, and KIR2DS4). Any geno-
type containing additional KIR genes is referred to as a BX,
as it contains at least 1 group B haplotype.19 The BX patients
were further subdivided into imputed BB haplotypes based
on the absence of the A haplotype genes KIR2DL3,
KIR2DL1 and KIR3DL1. Finally, genotypes were dichoto-
mized into telomeric and centromeric A and B haplotype mo-
tifs according to published algorithms.20
TABLE 1.
Patient characteristics
KIR haplotype
AA BX
P(n = 176) (n = 473)
Patient age at transplantation
Median (range) 50 (1–75) 50 (0–79) 0.91
Sex (n, %)
Male 116 (66) 309 (65) 0.89
Female 60 (34) 164 (35)
Center (n, %)
Basel 23 (13) 83 (18) 0.26
Bern 29 (17) 70 (15)
Geneva 28 (16) 67 (14)
Lausanne 36 (21) 66 (14)
St. Gallen 4 (2) 11 (2)
Zürich 56 (32) 176 (37)
No. HLA-A/B/DR-mismatches (n, %)
0-2 13 (7) 47 (10) 0.10
3-4 53 (30) 150 (32)
5-6 94 (53) 208 (44)
Missing 16 (9) 68 (14)
Antibody induction (n, %)
Anti-CD25 MAb 104 (59) 282 (60) 0.98
ATG 32 (18) 87 (18)
None 40 (23) 62 (13)
Maintenance immunosuppression (n, %)
Tacrolimus 120 (68) 317 (67) 0.78
Cyclosporine 65 (37) 176 (37) 0.95
Prednisone 161 (92) 425 (90) 0.53
MMF 163 (93) 437 (92) 0.92
mTOR 22 (13) 62 (13) 0.84
Antiviral prophylaxis (n, %)
Ganciclovir/valgancyclovir 68 (39) 179 (38) 0.85
Acyclovir/valacyclovir 23 (13) 36 (8) 0.03
Organ transplant (n, %)
Heart 23 (31) 51 (69) 0.88
Kidney 78 (27) 213 (73)
Liver 50 (27) 138 (73)
Lung 25 (26) 71 (74)
ATG indicates anti-thymocyte globulin; MMF, mycophenolate mofetil; mTOR, mechanistic target of
rapamycin inhibitor (i.e., sirolimus or everolimus).
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Diagnosis of Viral Infections
Recipients of kidney transplants were screened for BKPyV
replication by qPCR in blood and urine at minimum once
every 3 months in the first year after transplantation. Addi-
tionally, BKPyV replication was assessed by qPCR when
clinically indicated. Patients receiving organ transplants
other than kidney were not regularly screened for BKPyV.
The EBV screening guidelines differ between the involved
study centers. In 121 patients, EBV replication was
assessed 6 and 12 months after transplantation. The re-
maining patients were tested for EBV based on clinical sus-
picion. In both cases, EBV replication was detected by
qPCR from the blood. Infection with herpes simplex virus
(HSV) was diagnosed clinically and confirmed by qPCR
only exceptionally in single cases. Infection with varicella
zoster was clinically diagnosed in totally 28 patients. Of
these, diagnosis was reassessed and confirmed by qPCR
in 17 patients. The serological status for EBV, HSV, and
VZV of donors and recipients before transplantation is
indicated in Table 2.
Statistical Analysis
Patient characteristics were compared by Mann-Whitney
U test or Pearsonχ2 test, where appropriate. The cumulative
incidence of viral infection/replication events (± standard er-
ror) was estimated using death and graft loss as competing
risks. Patients were grouped into those carrying 2 KIRA hap-
lotypes (AA) versus those carrying 1 or 2 KIR B haplotypes
(BX). Only the first episode of infection with each pathogen
was considered in each patient. Cox regression was used
for multivariable analyses, adjusting for induction immuno-
suppression, number of HLA mismatches (HLA-A/-B/-DR),
graft rejection and respective therapy, type of organ trans-
planted, for recipient pretransplant serology, and antiviral
prophylaxis (val-/ganciclovir and val-/acyclovir) in the case
of herpes virus infections. All statistical analyses were per-
formed with SPSS v.21 (IBM Corp, Armonk, NY).
RESULTS
The following numbers of infectious episodes were recorded
in this cohort: cytomegalovirus, 289; EBV, 98; HSV, 69; BK vi-
rus (BKV), 63; rhinovirus, 32; hepatitis C virus, 29, VZV, 28;
influenza virus, 20; respiratory syncytial virus, 16. Because viral
infections of the respiratory tract are frequent, and only in ami-
nority of cases identification of the pathogen responsible is
attempted, we excluded rhinovirus, influenza virus, and respi-
ratory syncytial virus from the analysis. Cytomegalovirus and
hepatitis C virus were also excluded because the effect of KIR
genotype on virus replication/infection has been described in
previous studies.6-8
Analysis of the cumulative incidences of viral infections re-
vealed that presence of a KIR-BX haplotype in the patient
provided relative protection from VZV replication. The
TABLE 2.
Infection status patients and donors
KIR haplotype
AA BX
P(n = 176) (n = 473)
EBV serology (n, %)
D−/R− 2 (1) 5 (1) 0.95
D−/R+ 7 (4) 26 (6)
D+/R− 11 (6) 29 (6)
D+/R+ 145 (82) 387 (82)
Missing 11 (6) 26 (6)
HSV serology (n, %)
D−/R− 3 (2) 16 (3) 0.22
D−/R+ 14 (8) 19 (4)
D+/R− 12 (7) 35 (7)
D+/R+ 50 (28) 150 (32)
Missing 97 (55) 253 (54)
VZV serology (n, %)
D−/R− 3 (2) 2 (0) 0.33
D−/R+ 10 (6) 24 (5)
D+/R− 3 (2) 14 (3)
D+/R+ 77 (44) 198 (42)
Missing 83 (47) 235 (50)
FIGURE 1. Cumulative incidence of varicella zoster (VZV), EBV, HSV, and BKPyV. Solid lines represent patients homozygous for the KIR-A
haplotype (AA), whereas dashed lines represent patients carrying 1 or 2 KIR B haplotypes (BX). P value derived from Gray test.
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2-year cumulative incidence of VZV infection was signifi-
cantly lower in KIR-BX haplotype patients (3% ± 1%) com-
pared to AA individuals (7% ± 2%, P = 0.02, Figure 1).
A trend toward lower rates of EBV replication was also ob-
served (2-year cumulative incidence 9% ± 1% versus
13% ± 3%); however, this difference did not reach the level
of statistical significance (P = 0.12, Figure 1). For the remain-
ing viruses, no effect of KIR haplotype was observed: HSV,
9% ± 1% versus 11% ± 2% (P = 0.45); and BKPyV,
15% ± 2% versus 15% ± 4% (P = 0.75, Figure 1) for BX
and AA haplotype patients, respectively.
To further address the correlation of KIR haplotype and
protection from VZV, we grouped patients by imputed hap-
lotypes (AA versus AB versus BB) and by centromeric and
telomeric KIR A and B motifs. This analysis revealed that
protection fromVZVreactivation was related to centromeric
(P = 0.05) rather than telomeric (P = 0.44) KIR B motifs
(Figure 2, upper and middle panels). Furthermore, we found
that 1 haplotype B was associated with relative protec-
tion from VZV reactivation, as rates in AB and in BB
patients were comparable (6% ± 2% versus 7% ± 3%, re-
spectively, Figure 2, lower panel). Finally, multivariable
analysis confirmed a statistically significant protective effect
of KIR BX status regarding posttransplant VZV infection
(hazard rate vsAAhaplotype: 0.43, 95% confidence interval,
0.21-0.91; P = 0.03). Similarly, the risk for EBV replication
after adjustment for covariates was reduced still without
reaching the level of statistical significance (hazard ratio,
0.68; 95% confidence interval, 0.41-1.12; P = 0.13).
DISCUSSION
In this study, we report that patients carrying KIR B haplo-
types benefit from relative protection regarding VZV reacti-
vation during the first 2 years after SOT. This effect
appeared to be specifically linked to VZV as no effect was
seen on HSVand BKV replication. The EBV replication was
less frequent among carriers of B haplotypes, but this differ-
ence did not reach statistical significance, presumably in part
due to the low rate of events for this type of complication. It is
therefore notable that the data presented here suggest suscep-
tibility to activating KIRs for 1 or possibly 2 further members
of the herpes virus family besides cytomegalovirus (CMV).
To further disclose which activating KIRs may be involved
in immunological control of VZV, we divided activating
KIRs in relation to KIR2DS4 as previously described in cen-
tromeric and telomeric genes.20 These analyses illustrate that
centromeric rather than telomeric KIR loci are associated
with protection from VZV, reducing the number of potential
candidate loci mainly to 3: the inhibitory KIR2DL2 and the
activating receptors KIR2DS2 and KIR2DS3. KIR2DS3 is
an unlikely candidate, as the most prevalent alleles are not
expressed on the cell surface. Unfortunately, further genotype/
phenotype correlations will add little to discriminate between
the effect of these 2 genes, as they are in almost perfect linkage
disequilibrium.21 Another limitation of this study derives from
the fact that diagnosis of viral replication was based on clinical
suspicion for some of the viruses analyzed, implying that sub-
clinical replication may have been missed in some instances.
Our findings stand in line with previous work exploring
the physiological relevance of activating KIR. Several recent
studies have described a protective effect of activating KIRs
against CMV replication in different settings of immunosup-
pression.6,7 After SOTor hematopoietic stem cell transplanta-
tion, when the adaptive immune system is pharmacologically
suppressed, patients with a higher number of (haplotype B) ac-
tivating KIR genes experience relative protection from CMV
replication.22,23 Further clinical conditions associated with
KIR B haplotypes are reduced relapse rates in AML patients
after allogeneic hematopoietic stem cell transplantation (if
KIR B genes are present in the donor); and a reduced risk of
preeclampsia in women carrying activating KIR genes.24,25
These associations indicate that activating KIR receptors
might recognize patterns on wide range of different potential
target cells. We therefore explored the possibility that KIR
haplotype associates with the susceptibility to other opportu-
nistic infections in patients under pharmacological immuno-
suppression. Apart from CMV and hepatitis C,6-8 limited
knowledge regarding potential roles for KIR and NK cells in
antiviral immunity exists. No effect of KIR haplotype was seen
regarding replication of HSVand BKPyV, which stands some-
what in contradiction to previous studies partly done in
healthy donors.9,10 However, this may reflect the different role
for NK cells in patients with compromised adaptive immunity
FIGURE 2. Cumulative incidence of VZV events in patients grouped
by telomeric and centromeric KIR-B haplotype content (upper and
middle panel) and by imputed haplotypes (lower panel). For the upper
and middle panels, solid lines represent patients homozygous for the
KIR-A haplotype (AA), whereas dashed lines represent patients carry-
ing 1 or 2 KIR B haplotypes (BX). P value derived from Gray test.
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and the sites of reactivation. In summary, we find that
telomeric B-haplotype KIR genes are associated with protec-
tion fromVZVreactivation after SOT. If confirmed, these data
may have an impact on VZV prophylaxis in these patients.
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